Cycle & Carriage Bintang launches its new Mazda6

PETALING JAYA: Cycle & Carriage Bintang Bhd (CCB), which has unveiled a new sports sedan Mazda6, aims to capture 10% to 15% market share in the 2-litre passenger car segment in Malaysia in the next 12 months. 

CCB, a key member of Jardine Cycle & Carriage Group, is a major dealer for Mercedes-Benz products in Malaysia and the sole distributor for Mazda and Peugeot products in Malaysia. 

Its managing director Steven Foster said given the tremendous response for the group’s 2-litre passenger cars in the past, CCB believed that it could easily achieve the target. 

“I am confident we can achieve this target. With the price range between RM140,000 and RM170,000 for a 2-litre car, we believe that it is affordable for the Malaysian people,” he told reporters after the launching of Mazda6 in Petaling Jaya yesterday. 

Mazda6, retailed at RM159,668 comes with eight airbags to guarantee the safety of its passengers. 

It has got an in-line four cylinder, DOHC and 16-valve engine with a maximum power of 140kw at 6,000rpm and maximum torque output of 181NM at 4,100 to 5,000 rpm. 

Foster said the first shipment involving 100 units of Mazda6 have been fully booked. 

He said CCB also hoped to launch the series of 2.3-litre of Mazda6 by early next year. Another model, the Mazda5, is also expected to be launched soon. 

He said the group wants to make Mazda one of the most reliable cars in the world. – Bernama  

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3

Next In Business News

Malaysia Airlines extends flexibility for passengers to change travel dates
MAA: Vehicle sales up 33% to 63,878 units in March
FBM KLCI ends flat on lack of fresh catalysts
Grab considering secondary Singapore listing after US SPAC merger - sources
UEM Edgenta denies allegations, claims against its subsidiary by AZSB
Bank Negara revises foreign exchange notices
Tencent raises US$4.2bil in its second major bond deal in a year
World stocks near record highs as China, U.S. data back global recovery hopes
Oil steady climbs to four-week high on strong China data, demand revival
Sinopharm to inject US$4.6 bln vaccine assets into unit Tiantan Biological

Stories You'll Enjoy